


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15 (Canceled)

16. (New) A compound having the general formula I:



wherein

R1, R2, R3, R4, R5, are each independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃ aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF₃, OR₁₈, SR₁₈, OC₁₋₆ alkyl, OC₂₋₆ alkylNR₁₈R₁₉, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R₁₈, C₁₋₆ alkylCO₂R₁₈, CONR₁₈R₁₉, C₁₋₆alkylCONR₁₈R₁₉, NR₁₈R₁₉, C₁₋₆ alkylNR₁₈R₁₉, NR₂₀C₁₋₆ alkylNR₁₈R₁₉, C₁₋₆alkylNR₂₀C₁₋₆ alkylNR₁₈R₁₉, NR₁₈CO₂R₁₉, C₁₋₆ alkylNR₁₈CO₂R₁₉, C₁₋₆ alkylNR₂₀CONR₁₈R₁₉, NR₂₀CONR₁₈R₁₉, C₁₋₆ alkylNR₁₈SO₂R₁₉, NR₁₈SO₂R₁₉;

R18, R19 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄alkyl aryl, C₁₋₄alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C₁₋₄alkyl;

R6 is selected from H, C₁₋₄ alkyl,

R7 is selected from H, C₁₋₄ alkyl, SH, CN;

R8 is selected from OR9, NR9R10;

R9, R10 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkylCO₂H, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11;

R11 is selected from H, C₁₋₄ alkyl.

17. (New) A compound according to claim 16 wherein:

R1, R2, R3, R4 and R5 are each independently selected from H, OH, OC₁₋₄ alkyl, OC₁₋₄ alkylaryl, C₁₋₄ alkyl, halogen;


R6 is selected from H, C₁₋₄ alkyl,

R7 is selected from H, C₁₋₄ alkyl, SH, CN;

R8 is selected from OH, NR9R10;

R9, R10 are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkylCO₂H.

18. (New) A compound having the general formula II:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO₂, CN, C₁₋₆ alkyl, CF₃, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF₃, OR₁₈, SR₁₈, OC₁₋₆ alkyl, OC₂₋₆ alkylNR₁₈R₁₉, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC₁₋₆ alkylaryl, OC₁₋₆ alkylheteroaryl, OC₁₋₆ alkylcycloalkyl, OC₁₋₆ cycloheteroalkyl, CO₂R₁₈, C₁₋₆ alkylCO₂R₁₈, CONR₁₈R₁₉, C₁₋₆ alkylCONR₁₈R₁₉, NR₁₈R₁₉, C₁₋₆ alkylNR₁₈R₁₉, NR₂₀C₁₋₆ alkylNR₁₈R₁₉, C₁₋₆ alkylNR₂₀C₁₋₆ alkylNR₁₈R₁₉, NR₁₈COR₁₉, C₁₋₆ alkylNR₁₈COR₁₉, C₁₋₆ alkylNR₂₀CONR₁₈R₁₉, NR₂₀CONR₁₈R₁₉, C₁₋₆ alkylNR₁₈SO₂R₁₉, NR₁₈SO₂R₁₉;

R₁₈, R₁₉ are each independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkyl cycloheteroalkyl, aryl, heteroaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR₂₁;

R₂₀, R₂₁ are each independently selected from H, C₁₋₄alkyl;

R₁₁, R₁₂ are each independently selected from H, C₁₋₄ alkyl, halogen, OC₁₋₄ alkyl.

19. (New) A compound according to claim 18 wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H, C₁₋₄ alkyl, OC₁₋₄ alkyl, CO₂H, CN;

R11, R12 are each independently selected from H, C₁₋₄ alkyl.

20. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 16;

(b) a pharmaceutically acceptable diluent.

21. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 17;

(b) a pharmaceutically acceptable diluent.

22. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 18;

(b) a pharmaceutically acceptable diluent.

23. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 19;

(b) a pharmaceutically acceptable diluent.

24. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 16.

25. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 17.

26. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 18.

27. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 19.

28. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 20.

29. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 21.

30. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 22.

31. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 23.

32. (New) A method according to claim 24 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

33. (New) A method according to claim 25 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

34. (New) A method according to claim 26 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

35. (New) A method according to claim 27 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

36. (New) A method according to claim 28 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

37. (New) A method according to claim 29 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

38. (New) A method according to claim 30 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

39. (New) A method according to claim 31 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.